Investment update – Paraytec and Gyrometric

Summary by AI BETAClose X

Truetide plc has provided an investment update on its portfolio companies, Paraytec and Gyrometric. Paraytec, in which Truetide holds a 100% stake, has made a significant advancement in its CX300 instrument for detecting bacteria in blood, discovering small molecules that selectively bind to Gram-positive bacteria, a crucial step towards clinical application. Gyrometric Systems, where Truetide owns 21.43%, has successfully completed a US-UK project validating its patented technology for monitoring large journal bearings in wind turbines, addressing a critical gap in condition monitoring for these increasingly used components, with Gyrometric receiving nearly £300,000 from Innovate UK for its portion of the project.

Disclaimer*

Truetide PLC
02 September 2026
 

2 September 2026

Truetide plc
("Truetide", the "Company" or the "Group")

Investment update - Paraytec and Gyrometric

Truetide plc (AIM: TRUE), the investing company focused on technology and knowledge-intensive businesses, is pleased to announce an update on two companies within its investment portfolio, Paraytec Limited ("Paraytec") and Gyrometric Systems Limited ("Gyrometric").

Paraytec (Truetide owns 100% of the company) 
Paraytec develops high-performance specialist detectors for the analytical and life sciences instrumentation markets.

As previously reported, Paraytec is working on the development of the CX300 instrument to assist in the rapid diagnosis and treatment of bacteraemia, the presence of bacteria in the blood, which is found in the majority of patients with sepsis. Paraytec has also confirmed that its CX300 instrument can detect and discriminate Gram-positive and Gram-negative bacteria in a sample from human blood in approximately 90 minutes, which is significantly faster than the current Gram test which takes between 24 and 48 hours.

One of the challenges associated with the sensitive detection of Gram-positive bacteria in human fluids is the identification of an appropriate fluorescent molecule that selectively shows high-affinity binding to Gram-positive bacteria with no appreciable binding to Gram-negative bacteria.  

The Paraytec team has evaluated a wide range of proteins, including antibodies, reported to show selective binding to Gram-positive bacteria. They found that some of these showed very poor selectivity, while others have a tendency to form protein aggregates which appear as 'false positives' in Paraytec's CX300 detection system. 

In a new development, Paraytec has investigated some small molecules that are capable of binding directly to a specific motif that is uniquely present in Gram positive bacteria. Using fluorescently tagged versions of these molecules, the team has found they sensitively and stably bind to Gram-positive but not Gram-negative bacteria in our standard laboratory test.

The Paraytec team believes that this discovery is an important progression in the translation of the test from proof-of-concept to real-world application. The next stage will be to confirm the sensitivity of detection in clinically relevant human fluids such as blood and urine. 

Gyrometric (Truetide owns 21.43% of the company)
Gyrometric has successfully completed the US-UK Large Journal Bearing Validation and Measurement Project (the "Project"). The Project has demonstrated that Gyrometric's patented technology can monitor the condition of large journal bearings, an application in which conventional vibration-based monitoring does not work.

A monitoring gap in large wind turbines 

As wind turbines grow in size, the industry is moving from rolling element bearings to journal bearings in turbine drivetrains, in both gearboxes and main bearings. Journal bearings carry higher loads in a more compact space, have far fewer parts and have no rolling contact elements to fatigue. This gives them potentially unlimited operating lives and, being modular, a more straightforward in-field repair. They are already in serial application in wind turbine gearboxes and are increasingly regarded as the future for large turbine drivetrains.

That shift creates a monitoring gap. Conventional condition monitoring detects the fault frequencies generated as rolling elements pass over a defect and journal bearings produce no such signatures. Gyrometric's patented technology  instead digitally measures the movement of the rotating shaft itself, allowing wear to be detected where vibration-based systems cannot.

The Project
The Project was established to design and validate journal bearing for large wind turbines, together with the measurement systems needed for long-term field monitoring. The bearings developed are designed to be refurbished in situ, without dismantling the whole turbine, as presently required for current rolling contact designs. This development creates the potential for significant maintenance savings for operators and Gyrometric's monitoring equipment was installed and successfully monitored the bearing tests carried out at Kingsbury Inc, in Philadelphia, United States.

The Project was funded in the UK by Innovate UK, with Gyrometric as UK project lead; Gyrometric's portion of the Innovate UK award was just under £300,000 from a total Innovate UK budget of £570,000. US funding was provided by the National Offshore Wind Research and Development Consortium (the "NOWRDC"). UK participants were Gyrometric Systems Ltd (UK lead) and the Offshore Renewable Energy Catapult and Leonardo Testing Services, a Sheffield University spin-out. US participants were Tufts University, Kingsbury Inc, the National Laboratory of the Rockies (formerly the National Renewable Energy Laboratory), GE Vernova and the University of Reno.

 

Truetide plc

Tel: 01738 587555

Trevor Brown, Chief Executive Officer

Viv Hallam, Executive Director




Allenby Capital Limited (Nominated Adviser and Joint Broker)

Tel: 020 3328 5656

James Reeve / Ashur Joseph



AlbR Limited (Joint Broker)

Tel: 020 7469 0936

Duncan Vasey / Lucy Williams


 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings